Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL8721639 | 0.97 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1KCNJ1DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL28293684 | 0.97 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1KCNJ1DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL1505073 | 0.97 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1KCNJ1DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL28222242 | 0.95 | ALDH1A1 (0.40) | ALDH1A1L3MBTL1KCNJ1DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL4797963 | 0.91 | KCNJ1 (0.38) | ALDH1A1L3MBTL1KCNJ1DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL4431540 | 0.89 | ALDH1A1 (0.35) | ALDH1A1L3MBTL1KCNJ1DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL28538609 | 0.89 | ALDH1A1 (0.35) | ALDH1A1L3MBTL1KCNJ1DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL4208428 | 0.88 | KCNJ1 (0.40) | ALDH1A1L3MBTL1KCNJ1GLAHSD17B10 | |
| Trifluoroacetic Acid SCHEMBL3746765 | 0.87 | DPP4 (0.37) | ALDH1A1L3MBTL1KCNJ1DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL16467201 | 0.87 | ALDH1A1 (0.33) | ALDH1A1L3MBTL1KCNJ1DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116574086-A | Preparation method of rupatadine fumarate medicament | 广东九明制药有限公司 | 2023-08-11 | — | — | CN | claimed |
| CN-109438363-A | A kind of liquid phase high-purity scale synthetic method of ring (leucyl-arginyl) dipeptides salt | 陕西慧康生物科技有限责任公司 | 2019-03-08 | — | — | CN | claimed |
| CN-118206532-A | Preparation method of rupatadine fumarate and rupatadine fumarate | 广东九明制药有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20240150290-A1 | HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-05-09 | — | — | US | disclosed |
| CN-117510500-A | Preparation method of asperazepanones alkaloid and application of asperazepanones alkaloid as anti-inflammatory drug | 中国海洋大学 | 2024-02-06 | — | — | CN | disclosed |
| EP-4277895-A1 | HETEROCYCLIC P2Y 14 RECEPTOR ANTAGONISTS | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2023-11-22 | — | — | EP | disclosed |
| CN-116574086-A | Preparation method of rupatadine fumarate medicament | 广东九明制药有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-116574086-A | Preparation method of rupatadine fumarate medicament | 广东九明制药有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-11708346-B2 | Treatment and prevention of neuropathic pain with P2Y14 antagonists | SAINT LOUIS UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| US-11584736-B2 | Heterocyclic P2Y14 receptor antagonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-02-21 | — | — | US | disclosed |
| CN-115490796-A | High-efficiency ring-opening metathesis polymerization catalysis method | 上海交通大学 | 2022-12-20 | — | — | CN | disclosed |
| WO-2003072528-A2 | (SUBSTITUTED)ACYL DIPEPTIDYL INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| US-6528661-B2 | Providing atorvastatin ester derivative; converting the atorvastatin ester derivative to atorvastatin hemi-calcium with calcium hydroxide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-03-04 | — | — | US | disclosed |
| US-6492394-B1 | PROCOLLAGEN C-PROTEINASE INHIBITORS; TREATING FIBROTIC DISEASES | SYNTEX (U.S.A.) LLC | 2002-12-10 | — | — | US | disclosed |
| US-20020099224-A1 | Hydrolysis of [R (R*, R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-07-25 | — | — | US | disclosed |
| WO-2002043667-A2 | HYDROLYSIS OF [R(R*,R*)]-2-(4-FLUOROPHENYL)-β,δ -DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-06-06 | — | — | WO | disclosed |
| CN-1331674-A | Sulfonamide hydroxamates | HOFFMANN LA ROCHE (CH) | 2002-01-16 | — | — | CN | disclosed |
| EP-0291234-B1 | Peptidic human leukocyte elastase (HLE) inhibitors | ZENECA INC (US) | 1994-03-23 | — | — | EP | disclosed |
| US-5164371-A | HETEROCYCLIC KETONES | ICI AMERICAS INC. (US) | 1992-11-17 | — | — | US | disclosed |
| EP-0291234-A2 | Peptidic human leukocyte elastase (HLE) inhibitors | ZENECA INC. (US) | 1988-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708346-B2 | Treatment and prevention of neuropathic pain with P2Y14 antagonists | P2RY14, P2RY4, P2RY13 | ALDH1A1 2346/4885L3MBTL1 4472/4885KCNJ1 568/4885 |
| US-11584736-B2 | Heterocyclic P2Y14 receptor antagonists | P2RY14, P2RY1, P2RY13 | ALDH1A1 2703/4885L3MBTL1 3247/4885KCNJ1 421/4885 |
| US-20020099224-A1 | Hydrolysis of [R (R*, R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide | HMGCR, DHCR7, GRHPR | ALDH1A1 1986/4885L3MBTL1 4546/4885KCNJ1 2320/4885 |
| US-20240150290-A1 | HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS | P2RY14, P2RY1, P2RY11 | ALDH1A1 2984/4885L3MBTL1 2752/4885KCNJ1 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.